Eisai’s experimental drug clears key Alzheimer’s brain protein by up to 90%

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Eisai presented data at the Alzheimer’s Association International Conference (AAIC) 2026 showing that investigational anti-MTBR antibody etalanetug (E2814) reduced levels of the tau tangle-specific biomarker eMTBR-tau243 in people with dominantly inherited Alzheimer’s disease (DIAD).

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Windward Bio raises $251m with Sanofi buying in

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE